- Home
- STLA vs RVMD Comparison
STLA vs RVMD Comparison
Compare STLA & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STLA | RVMD |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | Netherlands | United States |
| Employees | N/A | 883 |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 19.2B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | STLA | RVMD |
|---|---|---|
| Price | $7.18 | $139.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | $11.59 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 17.8M | 3.7M |
| Earning Date | 02-26-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.18 | N/A |
| Revenue Next Year | $3.50 | $533.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $34.00 |
| 52 Week High | $12.22 | $155.70 |
Technical Indicators
Market Signals| Indicator | STLA | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 60.59 |
| Support Level | $7.07 | $93.39 |
| Resistance Level | $10.31 | $155.70 |
| Average True Range (ATR) | 0.23 | 7.75 |
| MACD | -0.14 | -0.59 |
| Stochastic Oscillator | 8.57 | 36.30 |
Price Performance
Historical ComparisonAbout STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.